NCT07233720Recruiting
Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
A Multicenter Prospective Real-world Study of Zanubrutinib Combined With Rituximab (ZR) in the First-line Treatment for Patients With Marginal Zone Lymphoma (MZL)
Source: ClinicalTrials.gov · Last updated 18 Nov 2025
Brief summary (registry, in English)
This is a prospective single arm, multi-center, real-world study to observe the efficacy and safety of ZR (Zanubrutinib combined with Rituximab) in the first-line treatment for patients with marginal zone lymphoma (MZL).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 8 Jul 2025
- Start date
- 18 Nov 2025
- Primary completion date
- Jun 2028
- Lead sponsor
- Henan Cancer Hospital
- Diseases
- Childhood cancers
- NCT number
- NCT07233720
What you commit to
- Study type: Observational
- Planned participants: 30
- From 18 Nov 2025 to the primary completion date, Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- In addition to zanubrutinib and rituximab, other anti-tumor drug treatments were also received simultaneously (except for glucocorticoids aimed at controlling symptoms before formal treatment).
Other illness
- Other malignant tumor history or active malignant tumor need be treated
Who the study is looking for
- Patients with CD20-positive marginal zone lymphoma diagnosed by histopathology
- First-line treatment with the combination regimen of zanubrutinib and rituximab
- No receiving systematic treatment before enrollment
- Having at least one measurable lesions. Measurable lesions were defined as: the longest diameter of lymph node lesions in CT cross-sectional images \> 1.5 cm, or the longest diameter of the extranodal lesion is greater than 1.0cm
- The patients voluntarily joined this study, signed the informed consent form, had good compliance and cooperated with the follow-up.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university Coordinator of this site? Confirm its status | Zhengzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.